These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 26069894)

  • 1. Inflammatory bowel disease patients are frequently nonadherent to scheduled induction and maintenance infliximab therapy: A Canadian cohort study.
    Ma C; Evaschesen CJ; Gracias G; Huang VW; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    Can J Gastroenterol Hepatol; 2015; 29(6):309-14. PubMed ID: 26069894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to Infliximab Treatment in a Pediatric Inflammatory Bowel Disease Cohort.
    Vitale DS; Greenley RN; Lerner DG; Mavis AM; Werlin SL
    J Pediatr Gastroenterol Nutr; 2015 Oct; 61(4):408-10. PubMed ID: 25885878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel Disease.
    van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
    J Pediatr Gastroenterol Nutr; 2019 Jun; 68(6):847-853. PubMed ID: 30633108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Tolerability of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease.
    Ma D; Wong W; Aviado J; Rodriguez C; Wu H
    Am J Gastroenterol; 2019 Feb; 114(2):352-354. PubMed ID: 30333541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients.
    Kane SV; Chao J; Mulani PM
    Adv Ther; 2009 Oct; 26(10):936-46. PubMed ID: 19838649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Tolerability and Efficacy of Rapid Infliximab Infusions in Patients with Inflammatory Bowel Disease.
    Qazi T; Shah B; El-Dib M; Farraye FA
    Dig Dis Sci; 2016 Feb; 61(2):589-96. PubMed ID: 26441281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory bowel disease: healthcare costs for patients who are adherent or non-adherent with infliximab therapy.
    Wan GJ; Kozma CM; Slaton TL; Olson WH; Feagan BG
    J Med Econ; 2014 Jun; 17(6):384-93. PubMed ID: 24673303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid Infliximab Infusion in Children: A Multicenter Retrospective Cohort Study.
    Lev-Tzion R; Assa A; Yerushalmi B; Lahad A; Friedman M; Ledder O; Turner D
    J Pediatr Gastroenterol Nutr; 2017 Nov; 65(5):e101-e103. PubMed ID: 29064928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up.
    Caviglia R; Ribolsi M; Rizzi M; Emerenziani S; Annunziata M; Cicala M
    World J Gastroenterol; 2007 Oct; 13(39):5238-44. PubMed ID: 17876895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of infliximab adherence on Crohn's disease-related healthcare utilization and inpatient costs.
    Carter CT; Waters HC; Smith DB
    Adv Ther; 2011 Aug; 28(8):671-83. PubMed ID: 21818671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors influencing acute infusion reactions in inflammatory bowel disease patients treated with infliximab in the era of scheduled maintenance therapy.
    Duron C; Goutte M; Pereira B; Bommelaer G; Buisson A
    Eur J Gastroenterol Hepatol; 2015 Jun; 27(6):705-11. PubMed ID: 25856689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The long-term outcome of anti-tumor necrosis factor-α therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel disease.
    Kolho KL; Sipponen T
    Scand J Gastroenterol; 2014 Apr; 49(4):434-41. PubMed ID: 24597837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study.
    Van Assche G; Vermeire S; Noman M; Amant C; Weyts E; Vleminckx A; Vermeyen MJ; Rutgeerts P
    J Crohns Colitis; 2010 Sep; 4(3):329-33. PubMed ID: 21122522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Frequency of Clinic Visits Was Not Associated with Medication Adherence or Outcome in Children with Inflammatory Bowel Diseases.
    Kluthe C; Tsui J; Spady D; Carroll M; Wine E; Huynh HQ
    Can J Gastroenterol Hepatol; 2018; 2018():4687041. PubMed ID: 29682493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does infliximab short infusion have a beneficial impact on the quality of life in patients with inflammatory bowel diseases? A single centre prospective evaluation.
    Principi M; Losurdo G; La Fortezza RF; Lopolito P; Lovero R; Grillo S; Bringiotti R; Ierardi E; Di Leo A
    J Gastrointestin Liver Dis; 2015 Jun; 24(2):165-70. PubMed ID: 26114175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Home Infliximab Infusions Are Associated With Suboptimal Outcomes Without Cost Savings in Inflammatory Bowel Diseases.
    Giese-Kim N; Wu M; Dehghan M; Sceats LA; Park KT
    Am J Gastroenterol; 2020 Oct; 115(10):1698-1706. PubMed ID: 32701731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors Associated with Discontinuation of Anti-TNF Inhibitors Among Persons with IBD: A Population-Based Analysis.
    Targownik LE; Tennakoon A; Leung S; Lix LM; Nugent Z; Singh H; Bernstein CN
    Inflamm Bowel Dis; 2017 Mar; 23(3):409-420. PubMed ID: 28221250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability of one hour 10 mg/kg infliximab infusions in patients with inflammatory bowel disease.
    Babouri A; Buisson A; Bigard MA; Peyrin-Biroulet L
    J Crohns Colitis; 2013 Mar; 7(2):129-33. PubMed ID: 22472090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonadherence to Biologic Therapies in Inflammatory Bowel Disease.
    Wentworth BJ; Buerlein RCD; Tuskey AG; Overby MA; Smolkin ME; Behm BW
    Inflamm Bowel Dis; 2018 Aug; 24(9):2053-2061. PubMed ID: 29668917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A nurse-led accelerated procedure for infliximab infusion is well tolerated and effective in patients with inflammatory bowel disease.
    Michielan A; Martinato M; Favarin A; Zanotto V; Caccaro R; Caruso A; Sturniolo GC; D'Incà R
    Dig Liver Dis; 2015 May; 47(5):372-7. PubMed ID: 25708258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.